R
Rotraud K. Saurenmann
Researcher at Boston Children's Hospital
Publications - 60
Citations - 3729
Rotraud K. Saurenmann is an academic researcher from Boston Children's Hospital. The author has contributed to research in topics: Arthritis & Juvenile rheumatoid arthritis. The author has an hindex of 27, co-authored 59 publications receiving 3261 citations. Previous affiliations of Rotraud K. Saurenmann include Winterthur Museum, Garden and Library & University of Zurich.
Papers
More filters
Journal ArticleDOI
A randomized, placebo‐controlled trial of infliximab plus methotrexate for the treatment of polyarticular‐course juvenile rheumatoid arthritis
Nicolino Ruperto,Daniel J. Lovell,Ruben Cuttica,Nick Wilkinson,Patricia Woo,Graciela Espada,Carine Wouters,Earl D. Silverman,Zsolt Balogh,Michael Henrickson,Maria Teresa Apaz,Eileen Baildam,Anders Fasth,Valeria Gerloni,Pekka Lahdenne,AM Prieur,Angelo Ravelli,Rotraud K. Saurenmann,M.L. Gamir,Nico M Wulffraat,László Maródi,Ross E. Petty,Rik Joos,Francesco Zulian,Deborah McCurdy,Barry L. Myones,K. Nagy,Peter Reuman,Ilona S. Szer,Suzanne Travers,A. Beutler,Greg Keenan,Jason Clark,Sudha Visvanathan,Adedigbo A. Fasanmade,Aparna Raychaudhuri,Alan M. Mendelsohn,Alberto Martini,Edward H. Giannini +38 more
TL;DR: Safety data indicated that the 6-mg/kg dose may provide a more favorable risk/benefit profile for infliximab in the treatment of juvenile rheumatoid arthritis, and achievement of the primary efficacy end point at 3 months did not differ significantly between inflIXimab-treated and placebo-treated patients.
Journal ArticleDOI
A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate.
Nicolino Ruperto,Kevin J. Murray,Valeria Gerloni,Nico M Wulffraat,Sheila Knupp Feitosa de Oliveira,Fernanda Falcini,Pavla Dolezalova,Maria Alessio,Ruben Burgos-Vargas,Fabrizia Corona,Richard Vesely,Helen E. Foster,Joyce Davidson,Francesco Zulian,Line Asplin,Eileen Baildam,Julia Garcia Consuegra,Huri Ozdogan,Rotraud K. Saurenmann,Rik Joos,Angela Pistorio,Pat Woo,Alberto Martini +22 more
TL;DR: This study shows that the plateau of efficacy of MTX in JIA is reached with parenteral administration of 15 mg/m(2)/week and that a further increase in dosage is not associated with any additional therapeutic benefit.
Journal ArticleDOI
Prevalence, risk factors, and outcome of uveitis in juvenile idiopathic arthritis: a long-term followup study
Rotraud K. Saurenmann,Alex V. Levin,Brian M. Feldman,J. B. Rose,Ronald M. Laxer,Rayfel Schneider,Earl D. Silverman +6 more
TL;DR: The long-term outcome of JIA-associated uveitis in patients diagnosed as having JIA at a single tertiary care center was excellent despite the high rate of complications.
Journal ArticleDOI
Epidemiology of Juvenile Idiopathic Arthritis in a Multiethnic Cohort Ethnicity as a Risk Factor
Rotraud K. Saurenmann,J. B. Rose,Pascal N. Tyrrell,Brian M. Feldman,Ronald M. Laxer,Rayfel Schneider,Earl D. Silverman +6 more
TL;DR: In this multiethnic cohort, European descent was associated with a significantly increased risk of developing JIA, and the distribution of JIA subtypes differed significantly across ethnic groups.
Journal ArticleDOI
Leflunomide or methotrexate for juvenile rheumatoid arthritis.
Earl D. Silverman,Richard Mouy,Lynn Spiegel,Lawrence Jung,Rotraud K. Saurenmann,Pekka Lahdenne,Gerd Horneff,Immaculada Calvo,Ilona S. Szer,Karen Simpson,John A. Stewart,Vibeke Strand +11 more
TL;DR: In patients with polyarticular juvenile rheumatoid arthritis, methotrexate and leflunomide both resulted in high rates of clinical improvement, but the rate was slightly greater for methotRexate.